- Home
- MTEK vs EDSA Comparison
MTEK vs EDSA Comparison
Compare MTEK & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- EDSA
- Stock Information
- Founded
- MTEK 2008
- EDSA 2015
- Country
- MTEK Israel
- EDSA Canada
- Employees
- MTEK N/A
- EDSA N/A
- Industry
- MTEK
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- EDSA Health Care
- Exchange
- MTEK Nasdaq
- EDSA Nasdaq
- Market Cap
- MTEK 17.6M
- EDSA 6.1M
- IPO Year
- MTEK 2022
- EDSA N/A
- Fundamental
- Price
- MTEK $5.03
- EDSA $1.73
- Analyst Decision
- MTEK
- EDSA Strong Buy
- Analyst Count
- MTEK 0
- EDSA 1
- Target Price
- MTEK N/A
- EDSA $21.00
- AVG Volume (30 Days)
- MTEK 392.5K
- EDSA 30.6K
- Earning Date
- MTEK 12-31-2024
- EDSA 02-07-2025
- Dividend Yield
- MTEK N/A
- EDSA N/A
- EPS Growth
- MTEK N/A
- EDSA N/A
- EPS
- MTEK N/A
- EDSA N/A
- Revenue
- MTEK $6,967,508.00
- EDSA N/A
- Revenue This Year
- MTEK N/A
- EDSA N/A
- Revenue Next Year
- MTEK N/A
- EDSA N/A
- P/E Ratio
- MTEK N/A
- EDSA N/A
- Revenue Growth
- MTEK 246.50
- EDSA N/A
- 52 Week Low
- MTEK $1.01
- EDSA $1.55
- 52 Week High
- MTEK $5.31
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- MTEK 86.56
- EDSA 31.51
- Support Level
- MTEK $2.11
- EDSA $1.73
- Resistance Level
- MTEK $5.31
- EDSA $1.99
- Average True Range (ATR)
- MTEK 0.56
- EDSA 0.19
- MACD
- MTEK 0.27
- EDSA 0.02
- Stochastic Oscillator
- MTEK 91.09
- EDSA 18.00
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.